byiShook Opinion
Feb 6, 2025 - 17:20
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. The post Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug appeared first on Investor's Business Daily.
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
The post Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug appeared first on Investor's Business Daily.